Prognostic Value of Melanoma Inhibitory Activity Protein in Localized Cutaneous Malignant Melanoma

Abstract

Background. Cutaneous malignant melanoma (CMM) is a heterogeneous disease, acknowledged for its lack of predictability regarding clinical evolution. In order to appreciate a patient's individual prognosis, an attempt is made to find new tumor markers that parallel the disease progression. Objective. To identify if melanoma inhibitory activity (MIA) protein could represent a tool for selecting high risk early stages melanoma patients. Method. Between 2008 and 2013, 155 patients with CMM were treated in our clinic. 84 of them were classified into stages I and II, according to TNM 2009. MIA serum concentration was measured in all patients and 50 healthy donors. A cut-off value of 9.4 ng/ml was established using the ROC curve. Results. All patients were followed up by periodic investigations every 6 months. We have noticed that 66% of patients with MIA serum values at diagnosis greater than 9.4 ng/mL have relapsed, while only 5% of patients with MIA serum concentration below the estimated threshold, recurred during the follow-up period (P = 0.000). The death risk was 12 times higher in pathological MIA group of patients (P = 0.0001). Conclusions. Our data suggest that MIA is an independent prognostic factor for patients with localized CMM.

Revisiting determinants of prognosis in cutaneous melanoma

“…In a cohort of 84 patients with stage I and II cutaneous melanoma who were followed prospectively, high versus low serum MIA concentrations were associated with increased recurrence (66% vs 5%) and reduced DFS at 4 years (30.3% vs 94.5%). 101 Serum levels of S100B, a protein involved in microtubule assembly and inhibition of the tumor suppressor p53, increase progressively in each stage of melanoma and associate negatively with survival. 102,103 C-reactive protein (CRP) is an acute-phase reactant that is elevated in numerous clinical scenarios, including states of infection, inflammation, and malignancy.…”

Tanapoxvirus lacking a neuregulin-like gene regresses human melanoma tumors in nude mice

“…It accounts for approximately 4% of all skin cancers, but for nearly 80% of all skin-cancer related deaths [1–3]. If not detected at the early stage, metastatic melanoma is highly aggressive with the five-year survival rate of approximately 15% [4]. Significant progress has been made in the development of treatment options for melanoma where current therapeutic options include surgery, chemotherapy, radiotherapy, immunotherapy, cryotherapy, and targeted drugs.…”

Melanoma Inhibitory Activity and regional lymph node status in malignant melanoma patients

“…MIA was measured preoperatively in all patients. A cut-off value of 9.4 ng/mL was calculated using ROC curve [ 4 ]. Patients were divided in four groups according to RLN status (N0/N1/N2/N3).…”